https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-scemblix-asciminib-date-of-authorisation-25-08-2022-revision-15-status-authorised-ms/ 2026-07-20T15:16:21+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-scemblix-asciminib-date-of-authorisation-25-08-2022-revision-15-status-authorised-th/ 2026-07-20T15:16:20+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-scemblix-asciminib-date-of-authorisation-25-08-2022-revision-15-status-authorised-vi/ 2026-07-20T15:16:20+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-scemblix-asciminib-date-of-authorisation-25-08-2022-revision-15-status-authorised-id/ 2026-07-20T15:16:19+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-scemblix-asciminib-date-of-authorisation-25-08-2022-revision-15-status-authorised-ar/ 2026-07-20T15:16:17+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-scemblix-asciminib-date-of-authorisation-25-08-2022-revision-15-status-authorised-ru/ 2026-07-20T15:16:17+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-scemblix-asciminib-date-of-authorisation-25-08-2022-revision-15-status-authorised-es/ 2026-07-20T15:16:16+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-scemblix-asciminib-date-of-authorisation-25-08-2022-revision-15-status-authorised-pt/ 2026-07-20T15:16:15+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-scemblix-asciminib-date-of-authorisation-25-08-2022-revision-15-status-authorised-ja/ 2026-07-20T15:16:14+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-scemblix-asciminib-date-of-authorisation-25-08-2022-revision-15-status-authorised-de/ 2026-07-20T15:16:13+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-scemblix-asciminib-date-of-authorisation-25-08-2022-revision-15-status-authorised-fr/ 2026-07-20T15:16:12+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-scemblix-asciminib-date-of-authorisation-25-08-2022-revision-15-status-authorised-zh-tw/ 2026-07-20T15:16:11+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-ogsiveo-nirogacestat-date-of-authorisation-14-08-2025-revision-3-status-authorised-ms/ 2026-07-20T15:16:10+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-scemblix-asciminib-date-of-authorisation-25-08-2022-revision-15-status-authorised/ 2026-07-20T15:16:10+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-ogsiveo-nirogacestat-date-of-authorisation-14-08-2025-revision-3-status-authorised-vi/ 2026-07-20T15:16:08+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-ogsiveo-nirogacestat-date-of-authorisation-14-08-2025-revision-3-status-authorised-th/ 2026-07-20T15:16:07+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-ogsiveo-nirogacestat-date-of-authorisation-14-08-2025-revision-3-status-authorised-id/ 2026-07-20T15:16:06+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-ogsiveo-nirogacestat-date-of-authorisation-14-08-2025-revision-3-status-authorised-ar/ 2026-07-20T15:16:05+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-ogsiveo-nirogacestat-date-of-authorisation-14-08-2025-revision-3-status-authorised-ru/ 2026-07-20T15:16:05+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-ogsiveo-nirogacestat-date-of-authorisation-14-08-2025-revision-3-status-authorised-es/ 2026-07-20T15:16:04+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-ogsiveo-nirogacestat-date-of-authorisation-14-08-2025-revision-3-status-authorised-pt/ 2026-07-20T15:16:02+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-ogsiveo-nirogacestat-date-of-authorisation-14-08-2025-revision-3-status-authorised-ja/ 2026-07-20T15:15:59+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-ogsiveo-nirogacestat-date-of-authorisation-14-08-2025-revision-3-status-authorised-de/ 2026-07-20T15:15:58+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-ogsiveo-nirogacestat-date-of-authorisation-14-08-2025-revision-3-status-authorised-fr/ 2026-07-20T15:15:56+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-ogsiveo-nirogacestat-date-of-authorisation-14-08-2025-revision-3-status-authorised-zh-tw/ 2026-07-20T15:15:55+00:00 https://keshavmed.com/news/human-medicines-european-public-assessment-report-epar-ogsiveo-nirogacestat-date-of-authorisation-14-08-2025-revision-3-status-authorised/ 2026-07-20T15:15:52+00:00 https://keshavmed.com/news/unlocking-a-real-cure-for-hiv-viral-shock-and-kill-therapy-doherty-institute-fr/ 2026-07-20T12:18:13+00:00 https://keshavmed.com/news/unlocking-a-real-cure-for-hiv-viral-shock-and-kill-therapy-doherty-institute-zh-tw/ 2026-07-20T12:18:08+00:00 https://keshavmed.com/news/unlocking-a-real-cure-for-hiv-viral-shock-and-kill-therapy-doherty-institute/ 2026-07-20T12:18:05+00:00 https://keshavmed.com/news/a-single-once-daily-pill-combining-two-antiretrovirals-simplifies-hiv-treatment-as-demonstrated-by-a-phase-3-trial-science-media-centre-espana-ms/ 2026-07-20T12:17:57+00:00 https://keshavmed.com/news/a-single-once-daily-pill-combining-two-antiretrovirals-simplifies-hiv-treatment-as-demonstrated-by-a-phase-3-trial-science-media-centre-espana-vi/ 2026-07-20T12:17:54+00:00 https://keshavmed.com/news/a-single-once-daily-pill-combining-two-antiretrovirals-simplifies-hiv-treatment-as-demonstrated-by-a-phase-3-trial-science-media-centre-espana-th/ 2026-07-20T12:17:52+00:00 https://keshavmed.com/news/a-single-once-daily-pill-combining-two-antiretrovirals-simplifies-hiv-treatment-as-demonstrated-by-a-phase-3-trial-science-media-centre-espana-id/ 2026-07-20T12:17:49+00:00 https://keshavmed.com/news/a-single-once-daily-pill-combining-two-antiretrovirals-simplifies-hiv-treatment-as-demonstrated-by-a-phase-3-trial-science-media-centre-espana-ru/ 2026-07-20T12:17:45+00:00 https://keshavmed.com/news/a-single-once-daily-pill-combining-two-antiretrovirals-simplifies-hiv-treatment-as-demonstrated-by-a-phase-3-trial-science-media-centre-espana-ar/ 2026-07-20T12:17:43+00:00 https://keshavmed.com/news/a-single-once-daily-pill-combining-two-antiretrovirals-simplifies-hiv-treatment-as-demonstrated-by-a-phase-3-trial-science-media-centre-espana-es/ 2026-07-20T12:17:41+00:00 https://keshavmed.com/news/a-single-once-daily-pill-combining-two-antiretrovirals-simplifies-hiv-treatment-as-demonstrated-by-a-phase-3-trial-science-media-centre-espana-pt/ 2026-07-20T12:17:39+00:00 https://keshavmed.com/news/a-single-once-daily-pill-combining-two-antiretrovirals-simplifies-hiv-treatment-as-demonstrated-by-a-phase-3-trial-science-media-centre-espana-ja/ 2026-07-20T12:17:37+00:00 https://keshavmed.com/news/a-single-once-daily-pill-combining-two-antiretrovirals-simplifies-hiv-treatment-as-demonstrated-by-a-phase-3-trial-science-media-centre-espana-de/ 2026-07-20T12:17:35+00:00 https://keshavmed.com/news/a-single-once-daily-pill-combining-two-antiretrovirals-simplifies-hiv-treatment-as-demonstrated-by-a-phase-3-trial-science-media-centre-espana-fr/ 2026-07-20T12:17:33+00:00 https://keshavmed.com/news/a-single-once-daily-pill-combining-two-antiretrovirals-simplifies-hiv-treatment-as-demonstrated-by-a-phase-3-trial-science-media-centre-espana-zh-tw/ 2026-07-20T12:17:31+00:00 https://keshavmed.com/news/a-single-once-daily-pill-combining-two-antiretrovirals-simplifies-hiv-treatment-as-demonstrated-by-a-phase-3-trial-science-media-centre-espana/ 2026-07-20T12:17:29+00:00 https://keshavmed.com/news/single-daily-pill-could-replace-complicated-hiv-drug-schedules-medical-news-today-ms/ 2026-07-20T12:17:17+00:00 https://keshavmed.com/news/single-daily-pill-could-replace-complicated-hiv-drug-schedules-medical-news-today-vi/ 2026-07-20T12:17:15+00:00 https://keshavmed.com/news/single-daily-pill-could-replace-complicated-hiv-drug-schedules-medical-news-today-th/ 2026-07-20T12:17:13+00:00 https://keshavmed.com/news/single-daily-pill-could-replace-complicated-hiv-drug-schedules-medical-news-today-id/ 2026-07-20T12:17:10+00:00 https://keshavmed.com/news/single-daily-pill-could-replace-complicated-hiv-drug-schedules-medical-news-today-ru/ 2026-07-20T12:17:08+00:00 https://keshavmed.com/news/single-daily-pill-could-replace-complicated-hiv-drug-schedules-medical-news-today-ar/ 2026-07-20T12:17:06+00:00 https://keshavmed.com/news/single-daily-pill-could-replace-complicated-hiv-drug-schedules-medical-news-today-es/ 2026-07-20T12:17:04+00:00 https://keshavmed.com/news/single-daily-pill-could-replace-complicated-hiv-drug-schedules-medical-news-today-pt/ 2026-07-20T12:17:02+00:00 https://keshavmed.com/news/single-daily-pill-could-replace-complicated-hiv-drug-schedules-medical-news-today-ja/ 2026-07-20T12:17:00+00:00 https://keshavmed.com/news/single-daily-pill-could-replace-complicated-hiv-drug-schedules-medical-news-today-de/ 2026-07-20T12:16:58+00:00 https://keshavmed.com/news/single-daily-pill-could-replace-complicated-hiv-drug-schedules-medical-news-today-fr/ 2026-07-20T12:16:55+00:00 https://keshavmed.com/news/single-daily-pill-could-replace-complicated-hiv-drug-schedules-medical-news-today-zh-tw/ 2026-07-20T12:16:52+00:00 https://keshavmed.com/news/single-daily-pill-could-replace-complicated-hiv-drug-schedules-medical-news-today/ 2026-07-20T12:16:50+00:00 https://keshavmed.com/news/%e3%80%90blood%e3%80%913%e5%b9%b4%e9%9a%8f%e8%ae%bf%e8%af%81%e5%ae%9eliso-cel%e6%b2%bb%e7%96%973%e7%ba%bf%e5%8f%8a%e4%bb%a5%e4%b8%8a%e6%bb%a4%e6%b3%a1%e6%b7%8b%e5%b7%b4%e7%98%a4%e9%95%bf%e6%9c%9f-ms/ 2026-07-20T12:12:26+00:00 https://keshavmed.com/news/%e3%80%90blood%e3%80%913%e5%b9%b4%e9%9a%8f%e8%ae%bf%e8%af%81%e5%ae%9eliso-cel%e6%b2%bb%e7%96%973%e7%ba%bf%e5%8f%8a%e4%bb%a5%e4%b8%8a%e6%bb%a4%e6%b3%a1%e6%b7%8b%e5%b7%b4%e7%98%a4%e9%95%bf%e6%9c%9f-vi/ 2026-07-20T12:12:25+00:00 https://keshavmed.com/news/%e3%80%90blood%e3%80%913%e5%b9%b4%e9%9a%8f%e8%ae%bf%e8%af%81%e5%ae%9eliso-cel%e6%b2%bb%e7%96%973%e7%ba%bf%e5%8f%8a%e4%bb%a5%e4%b8%8a%e6%bb%a4%e6%b3%a1%e6%b7%8b%e5%b7%b4%e7%98%a4%e9%95%bf%e6%9c%9f-th/ 2026-07-20T12:12:24+00:00 https://keshavmed.com/news/%e3%80%90blood%e3%80%913%e5%b9%b4%e9%9a%8f%e8%ae%bf%e8%af%81%e5%ae%9eliso-cel%e6%b2%bb%e7%96%973%e7%ba%bf%e5%8f%8a%e4%bb%a5%e4%b8%8a%e6%bb%a4%e6%b3%a1%e6%b7%8b%e5%b7%b4%e7%98%a4%e9%95%bf%e6%9c%9f-id/ 2026-07-20T12:12:22+00:00 https://keshavmed.com/news/%e3%80%90blood%e3%80%913%e5%b9%b4%e9%9a%8f%e8%ae%bf%e8%af%81%e5%ae%9eliso-cel%e6%b2%bb%e7%96%973%e7%ba%bf%e5%8f%8a%e4%bb%a5%e4%b8%8a%e6%bb%a4%e6%b3%a1%e6%b7%8b%e5%b7%b4%e7%98%a4%e9%95%bf%e6%9c%9f-ru/ 2026-07-20T12:12:21+00:00 https://keshavmed.com/news/%e3%80%90blood%e3%80%913%e5%b9%b4%e9%9a%8f%e8%ae%bf%e8%af%81%e5%ae%9eliso-cel%e6%b2%bb%e7%96%973%e7%ba%bf%e5%8f%8a%e4%bb%a5%e4%b8%8a%e6%bb%a4%e6%b3%a1%e6%b7%8b%e5%b7%b4%e7%98%a4%e9%95%bf%e6%9c%9f-ar/ 2026-07-20T12:12:20+00:00 https://keshavmed.com/news/%e3%80%90blood%e3%80%913%e5%b9%b4%e9%9a%8f%e8%ae%bf%e8%af%81%e5%ae%9eliso-cel%e6%b2%bb%e7%96%973%e7%ba%bf%e5%8f%8a%e4%bb%a5%e4%b8%8a%e6%bb%a4%e6%b3%a1%e6%b7%8b%e5%b7%b4%e7%98%a4%e9%95%bf%e6%9c%9f-es/ 2026-07-20T12:12:19+00:00 https://keshavmed.com/news/%e3%80%90blood%e3%80%913%e5%b9%b4%e9%9a%8f%e8%ae%bf%e8%af%81%e5%ae%9eliso-cel%e6%b2%bb%e7%96%973%e7%ba%bf%e5%8f%8a%e4%bb%a5%e4%b8%8a%e6%bb%a4%e6%b3%a1%e6%b7%8b%e5%b7%b4%e7%98%a4%e9%95%bf%e6%9c%9f-pt/ 2026-07-20T12:12:18+00:00 https://keshavmed.com/news/%e3%80%90blood%e3%80%913%e5%b9%b4%e9%9a%8f%e8%ae%bf%e8%af%81%e5%ae%9eliso-cel%e6%b2%bb%e7%96%973%e7%ba%bf%e5%8f%8a%e4%bb%a5%e4%b8%8a%e6%bb%a4%e6%b3%a1%e6%b7%8b%e5%b7%b4%e7%98%a4%e9%95%bf%e6%9c%9f-ja/ 2026-07-20T12:12:17+00:00 https://keshavmed.com/news/%e3%80%90blood%e3%80%913%e5%b9%b4%e9%9a%8f%e8%ae%bf%e8%af%81%e5%ae%9eliso-cel%e6%b2%bb%e7%96%973%e7%ba%bf%e5%8f%8a%e4%bb%a5%e4%b8%8a%e6%bb%a4%e6%b3%a1%e6%b7%8b%e5%b7%b4%e7%98%a4%e9%95%bf%e6%9c%9f-de/ 2026-07-20T12:12:16+00:00 https://keshavmed.com/news/%e3%80%90blood%e3%80%913%e5%b9%b4%e9%9a%8f%e8%ae%bf%e8%af%81%e5%ae%9eliso-cel%e6%b2%bb%e7%96%973%e7%ba%bf%e5%8f%8a%e4%bb%a5%e4%b8%8a%e6%bb%a4%e6%b3%a1%e6%b7%8b%e5%b7%b4%e7%98%a4%e9%95%bf%e6%9c%9f-fr/ 2026-07-20T12:12:15+00:00 https://keshavmed.com/news/%e3%80%90blood%e3%80%913%e5%b9%b4%e9%9a%8f%e8%ae%bf%e8%af%81%e5%ae%9eliso-cel%e6%b2%bb%e7%96%973%e7%ba%bf%e5%8f%8a%e4%bb%a5%e4%b8%8a%e6%bb%a4%e6%b3%a1%e6%b7%8b%e5%b7%b4%e7%98%a4%e9%95%bf%e6%9c%9f-en/ 2026-07-20T12:12:14+00:00 https://keshavmed.com/news/%e3%80%90blood%e3%80%913%e5%b9%b4%e9%9a%8f%e8%ae%bf%e8%af%81%e5%ae%9eliso-cel%e6%b2%bb%e7%96%973%e7%ba%bf%e5%8f%8a%e4%bb%a5%e4%b8%8a%e6%bb%a4%e6%b3%a1%e6%b7%8b%e5%b7%b4%e7%98%a4%e9%95%bf%e6%9c%9f-zh-t/ 2026-07-20T12:12:13+00:00 https://keshavmed.com/news/%e3%80%90blood%e3%80%913%e5%b9%b4%e9%9a%8f%e8%ae%bf%e8%af%81%e5%ae%9eliso-cel%e6%b2%bb%e7%96%973%e7%ba%bf%e5%8f%8a%e4%bb%a5%e4%b8%8a%e6%bb%a4%e6%b3%a1%e6%b7%8b%e5%b7%b4%e7%98%a4%e9%95%bf%e6%9c%9f/ 2026-07-20T12:12:12+00:00 https://keshavmed.com/news/a%e5%9e%8b%e8%82%89%e6%af%92%e6%af%92%e7%b4%a0%e6%b2%bb%e7%a5%9e%e7%bb%8f%e6%ba%90%e6%80%a7%e8%86%80%e8%83%b1%e7%96%97%e6%95%88%e5%ae%89%e5%85%a8%e5%90%97%e7%a5%9e%e7%bb%8f%e6%ba%90%e6%80%a7%e8%86%80/ 2026-07-20T12:10:41+00:00 https://keshavmed.com/news/%e5%88%9b%e6%96%b0%e6%b3%a1%e6%b2%ab%e5%89%82%e5%9e%8b%e9%93%b6%e5%b1%91%e7%97%85%e8%8d%af%e7%89%a9%e6%81%a9%e9%80%82%e8%be%be%ef%bc%88%e5%8d%a1%e6%b3%8a%e4%b8%89%e9%86%87%e5%80%8d%e4%bb%96-ms/ 2026-07-20T12:08:34+00:00 https://keshavmed.com/news/%e5%88%9b%e6%96%b0%e6%b3%a1%e6%b2%ab%e5%89%82%e5%9e%8b%e9%93%b6%e5%b1%91%e7%97%85%e8%8d%af%e7%89%a9%e6%81%a9%e9%80%82%e8%be%be%ef%bc%88%e5%8d%a1%e6%b3%8a%e4%b8%89%e9%86%87%e5%80%8d%e4%bb%96-vi/ 2026-07-20T12:08:33+00:00 https://keshavmed.com/news/%e5%88%9b%e6%96%b0%e6%b3%a1%e6%b2%ab%e5%89%82%e5%9e%8b%e9%93%b6%e5%b1%91%e7%97%85%e8%8d%af%e7%89%a9%e6%81%a9%e9%80%82%e8%be%be%ef%bc%88%e5%8d%a1%e6%b3%8a%e4%b8%89%e9%86%87%e5%80%8d%e4%bb%96-th/ 2026-07-20T12:08:31+00:00 https://keshavmed.com/news/%e5%88%9b%e6%96%b0%e6%b3%a1%e6%b2%ab%e5%89%82%e5%9e%8b%e9%93%b6%e5%b1%91%e7%97%85%e8%8d%af%e7%89%a9%e6%81%a9%e9%80%82%e8%be%be%ef%bc%88%e5%8d%a1%e6%b3%8a%e4%b8%89%e9%86%87%e5%80%8d%e4%bb%96-id/ 2026-07-20T12:08:30+00:00 https://keshavmed.com/news/%e5%88%9b%e6%96%b0%e6%b3%a1%e6%b2%ab%e5%89%82%e5%9e%8b%e9%93%b6%e5%b1%91%e7%97%85%e8%8d%af%e7%89%a9%e6%81%a9%e9%80%82%e8%be%be%ef%bc%88%e5%8d%a1%e6%b3%8a%e4%b8%89%e9%86%87%e5%80%8d%e4%bb%96-ru/ 2026-07-20T12:08:29+00:00 https://keshavmed.com/news/%e5%88%9b%e6%96%b0%e6%b3%a1%e6%b2%ab%e5%89%82%e5%9e%8b%e9%93%b6%e5%b1%91%e7%97%85%e8%8d%af%e7%89%a9%e6%81%a9%e9%80%82%e8%be%be%ef%bc%88%e5%8d%a1%e6%b3%8a%e4%b8%89%e9%86%87%e5%80%8d%e4%bb%96-ar/ 2026-07-20T12:08:28+00:00 https://keshavmed.com/news/%e5%88%9b%e6%96%b0%e6%b3%a1%e6%b2%ab%e5%89%82%e5%9e%8b%e9%93%b6%e5%b1%91%e7%97%85%e8%8d%af%e7%89%a9%e6%81%a9%e9%80%82%e8%be%be%ef%bc%88%e5%8d%a1%e6%b3%8a%e4%b8%89%e9%86%87%e5%80%8d%e4%bb%96-es/ 2026-07-20T12:08:27+00:00 https://keshavmed.com/news/%e5%88%9b%e6%96%b0%e6%b3%a1%e6%b2%ab%e5%89%82%e5%9e%8b%e9%93%b6%e5%b1%91%e7%97%85%e8%8d%af%e7%89%a9%e6%81%a9%e9%80%82%e8%be%be%ef%bc%88%e5%8d%a1%e6%b3%8a%e4%b8%89%e9%86%87%e5%80%8d%e4%bb%96-pt/ 2026-07-20T12:08:26+00:00 https://keshavmed.com/news/%e5%88%9b%e6%96%b0%e6%b3%a1%e6%b2%ab%e5%89%82%e5%9e%8b%e9%93%b6%e5%b1%91%e7%97%85%e8%8d%af%e7%89%a9%e6%81%a9%e9%80%82%e8%be%be%ef%bc%88%e5%8d%a1%e6%b3%8a%e4%b8%89%e9%86%87%e5%80%8d%e4%bb%96-ja/ 2026-07-20T12:08:25+00:00 https://keshavmed.com/news/%e5%88%9b%e6%96%b0%e6%b3%a1%e6%b2%ab%e5%89%82%e5%9e%8b%e9%93%b6%e5%b1%91%e7%97%85%e8%8d%af%e7%89%a9%e6%81%a9%e9%80%82%e8%be%be%ef%bc%88%e5%8d%a1%e6%b3%8a%e4%b8%89%e9%86%87%e5%80%8d%e4%bb%96-de/ 2026-07-20T12:08:24+00:00 https://keshavmed.com/news/%e5%88%9b%e6%96%b0%e6%b3%a1%e6%b2%ab%e5%89%82%e5%9e%8b%e9%93%b6%e5%b1%91%e7%97%85%e8%8d%af%e7%89%a9%e6%81%a9%e9%80%82%e8%be%be%ef%bc%88%e5%8d%a1%e6%b3%8a%e4%b8%89%e9%86%87%e5%80%8d%e4%bb%96-fr/ 2026-07-20T12:08:22+00:00 https://keshavmed.com/news/%e5%88%9b%e6%96%b0%e6%b3%a1%e6%b2%ab%e5%89%82%e5%9e%8b%e9%93%b6%e5%b1%91%e7%97%85%e8%8d%af%e7%89%a9%e6%81%a9%e9%80%82%e8%be%be%ef%bc%88%e5%8d%a1%e6%b3%8a%e4%b8%89%e9%86%87%e5%80%8d%e4%bb%96-en/ 2026-07-20T12:08:21+00:00 https://keshavmed.com/news/%e5%88%9b%e6%96%b0%e6%b3%a1%e6%b2%ab%e5%89%82%e5%9e%8b%e9%93%b6%e5%b1%91%e7%97%85%e8%8d%af%e7%89%a9%e6%81%a9%e9%80%82%e8%be%be%ef%bc%88%e5%8d%a1%e6%b3%8a%e4%b8%89%e9%86%87%e5%80%8d%e4%bb%96-zh-tw/ 2026-07-20T12:08:20+00:00 https://keshavmed.com/news/%e5%88%9b%e6%96%b0%e6%b3%a1%e6%b2%ab%e5%89%82%e5%9e%8b%e9%93%b6%e5%b1%91%e7%97%85%e8%8d%af%e7%89%a9%e6%81%a9%e9%80%82%e8%be%be%ef%bc%88%e5%8d%a1%e6%b3%8a%e4%b8%89%e9%86%87%e5%80%8d%e4%bb%96/ 2026-07-20T12:08:19+00:00 https://keshavmed.com/news/fda-grants-approval-for-oral-decitabine-cedazuridine-with-venetoclax-in-newly-diagnosed-aml-oncodaily-ms/ 2026-07-20T11:16:29+00:00 https://keshavmed.com/news/fda-grants-approval-for-oral-decitabine-cedazuridine-with-venetoclax-in-newly-diagnosed-aml-oncodaily-vi/ 2026-07-20T11:16:27+00:00 https://keshavmed.com/news/fda-grants-approval-for-oral-decitabine-cedazuridine-with-venetoclax-in-newly-diagnosed-aml-oncodaily-th/ 2026-07-20T11:16:26+00:00 https://keshavmed.com/news/fda-grants-approval-for-oral-decitabine-cedazuridine-with-venetoclax-in-newly-diagnosed-aml-oncodaily-id/ 2026-07-20T11:16:25+00:00 https://keshavmed.com/news/fda-grants-approval-for-oral-decitabine-cedazuridine-with-venetoclax-in-newly-diagnosed-aml-oncodaily-ru/ 2026-07-20T11:16:24+00:00 https://keshavmed.com/news/fda-grants-approval-for-oral-decitabine-cedazuridine-with-venetoclax-in-newly-diagnosed-aml-oncodaily-ar/ 2026-07-20T11:16:22+00:00 https://keshavmed.com/news/fda-grants-approval-for-oral-decitabine-cedazuridine-with-venetoclax-in-newly-diagnosed-aml-oncodaily-es/ 2026-07-20T11:16:21+00:00 https://keshavmed.com/news/fda-grants-approval-for-oral-decitabine-cedazuridine-with-venetoclax-in-newly-diagnosed-aml-oncodaily-pt/ 2026-07-20T11:16:20+00:00 https://keshavmed.com/news/fda-grants-approval-for-oral-decitabine-cedazuridine-with-venetoclax-in-newly-diagnosed-aml-oncodaily-ja/ 2026-07-20T11:16:18+00:00 https://keshavmed.com/news/fda-grants-approval-for-oral-decitabine-cedazuridine-with-venetoclax-in-newly-diagnosed-aml-oncodaily-de/ 2026-07-20T11:16:17+00:00 https://keshavmed.com/news/fda-grants-approval-for-oral-decitabine-cedazuridine-with-venetoclax-in-newly-diagnosed-aml-oncodaily-fr/ 2026-07-20T11:16:16+00:00 https://keshavmed.com/news/fda-grants-approval-for-oral-decitabine-cedazuridine-with-venetoclax-in-newly-diagnosed-aml-oncodaily-zh-tw/ 2026-07-20T11:16:15+00:00 https://keshavmed.com/news/fda-grants-approval-for-oral-decitabine-cedazuridine-with-venetoclax-in-newly-diagnosed-aml-oncodaily/ 2026-07-20T11:16:13+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-rituximab-improves-pfs-in-pretreated-cll-cancernetwork-ms/ 2026-07-20T11:15:37+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-rituximab-improves-pfs-in-pretreated-cll-cancernetwork-vi/ 2026-07-20T11:15:35+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-rituximab-improves-pfs-in-pretreated-cll-cancernetwork-th/ 2026-07-20T11:15:34+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-rituximab-improves-pfs-in-pretreated-cll-cancernetwork-id/ 2026-07-20T11:15:33+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-rituximab-improves-pfs-in-pretreated-cll-cancernetwork-ru/ 2026-07-20T11:15:32+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-rituximab-improves-pfs-in-pretreated-cll-cancernetwork-ar/ 2026-07-20T11:15:31+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-rituximab-improves-pfs-in-pretreated-cll-cancernetwork-es/ 2026-07-20T11:15:27+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-rituximab-improves-pfs-in-pretreated-cll-cancernetwork-pt/ 2026-07-20T11:15:26+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-rituximab-improves-pfs-in-pretreated-cll-cancernetwork-ja/ 2026-07-20T11:15:25+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-rituximab-improves-pfs-in-pretreated-cll-cancernetwork-de/ 2026-07-20T11:15:24+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-rituximab-improves-pfs-in-pretreated-cll-cancernetwork-fr/ 2026-07-20T11:15:23+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-rituximab-improves-pfs-in-pretreated-cll-cancernetwork-zh-tw/ 2026-07-20T11:15:20+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-rituximab-improves-pfs-in-pretreated-cll-cancernetwork/ 2026-07-20T11:15:17+00:00 https://keshavmed.com/news/tuspetinib-plus-venetoclax-and-azacitidine-is-safe-and-effective-across-molecular-subgroups-in-newly-diagnosed-aml-onclive-ms/ 2026-07-20T11:14:53+00:00 https://keshavmed.com/news/tuspetinib-plus-venetoclax-and-azacitidine-is-safe-and-effective-across-molecular-subgroups-in-newly-diagnosed-aml-onclive-vi/ 2026-07-20T11:14:52+00:00 https://keshavmed.com/news/tuspetinib-plus-venetoclax-and-azacitidine-is-safe-and-effective-across-molecular-subgroups-in-newly-diagnosed-aml-onclive-th/ 2026-07-20T11:14:50+00:00 https://keshavmed.com/news/tuspetinib-plus-venetoclax-and-azacitidine-is-safe-and-effective-across-molecular-subgroups-in-newly-diagnosed-aml-onclive-id/ 2026-07-20T11:14:49+00:00 https://keshavmed.com/news/tuspetinib-plus-venetoclax-and-azacitidine-is-safe-and-effective-across-molecular-subgroups-in-newly-diagnosed-aml-onclive-ru/ 2026-07-20T11:14:47+00:00 https://keshavmed.com/news/tuspetinib-plus-venetoclax-and-azacitidine-is-safe-and-effective-across-molecular-subgroups-in-newly-diagnosed-aml-onclive-ar/ 2026-07-20T11:14:45+00:00 https://keshavmed.com/news/tuspetinib-plus-venetoclax-and-azacitidine-is-safe-and-effective-across-molecular-subgroups-in-newly-diagnosed-aml-onclive-es/ 2026-07-20T11:14:43+00:00 https://keshavmed.com/news/tuspetinib-plus-venetoclax-and-azacitidine-is-safe-and-effective-across-molecular-subgroups-in-newly-diagnosed-aml-onclive-pt/ 2026-07-20T11:14:41+00:00 https://keshavmed.com/news/tuspetinib-plus-venetoclax-and-azacitidine-is-safe-and-effective-across-molecular-subgroups-in-newly-diagnosed-aml-onclive-ja/ 2026-07-20T11:14:40+00:00 https://keshavmed.com/news/tuspetinib-plus-venetoclax-and-azacitidine-is-safe-and-effective-across-molecular-subgroups-in-newly-diagnosed-aml-onclive-de/ 2026-07-20T11:14:38+00:00 https://keshavmed.com/news/tuspetinib-plus-venetoclax-and-azacitidine-is-safe-and-effective-across-molecular-subgroups-in-newly-diagnosed-aml-onclive-fr/ 2026-07-20T11:14:36+00:00 https://keshavmed.com/news/tuspetinib-plus-venetoclax-and-azacitidine-is-safe-and-effective-across-molecular-subgroups-in-newly-diagnosed-aml-onclive-zh-tw/ 2026-07-20T11:14:34+00:00 https://keshavmed.com/news/tuspetinib-plus-venetoclax-and-azacitidine-is-safe-and-effective-across-molecular-subgroups-in-newly-diagnosed-aml-onclive/ 2026-07-20T11:14:27+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-shows-promising-results-in-cll-oncology-news-central-ms/ 2026-07-20T11:14:03+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-shows-promising-results-in-cll-oncology-news-central-vi/ 2026-07-20T11:14:02+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-shows-promising-results-in-cll-oncology-news-central-th/ 2026-07-20T11:14:00+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-shows-promising-results-in-cll-oncology-news-central-id/ 2026-07-20T11:13:59+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-shows-promising-results-in-cll-oncology-news-central-ru/ 2026-07-20T11:13:58+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-shows-promising-results-in-cll-oncology-news-central-ar/ 2026-07-20T11:13:57+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-shows-promising-results-in-cll-oncology-news-central-es/ 2026-07-20T11:13:55+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-shows-promising-results-in-cll-oncology-news-central-pt/ 2026-07-20T11:13:53+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-shows-promising-results-in-cll-oncology-news-central-ja/ 2026-07-20T11:13:52+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-shows-promising-results-in-cll-oncology-news-central-de/ 2026-07-20T11:13:49+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-shows-promising-results-in-cll-oncology-news-central-fr/ 2026-07-20T11:13:48+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-shows-promising-results-in-cll-oncology-news-central-zh-tw/ 2026-07-20T11:13:45+00:00 https://keshavmed.com/news/pirtobrutinib-plus-venetoclax-shows-promising-results-in-cll-oncology-news-central/ 2026-07-20T11:13:41+00:00 https://keshavmed.com/news/identifying-biomarkers-of-therapeutic-resistance-with-lorlatinib-in-patients-with-alk-positive-advanced-nsclc-cancer-nursing-today-ms/ 2026-07-20T11:11:00+00:00 https://keshavmed.com/news/identifying-biomarkers-of-therapeutic-resistance-with-lorlatinib-in-patients-with-alk-positive-advanced-nsclc-cancer-nursing-today-vi/ 2026-07-20T11:10:57+00:00 https://keshavmed.com/news/identifying-biomarkers-of-therapeutic-resistance-with-lorlatinib-in-patients-with-alk-positive-advanced-nsclc-cancer-nursing-today-th/ 2026-07-20T11:10:54+00:00 https://keshavmed.com/news/identifying-biomarkers-of-therapeutic-resistance-with-lorlatinib-in-patients-with-alk-positive-advanced-nsclc-cancer-nursing-today-id/ 2026-07-20T11:10:51+00:00 https://keshavmed.com/news/identifying-biomarkers-of-therapeutic-resistance-with-lorlatinib-in-patients-with-alk-positive-advanced-nsclc-cancer-nursing-today-ru/ 2026-07-20T11:10:48+00:00 https://keshavmed.com/news/identifying-biomarkers-of-therapeutic-resistance-with-lorlatinib-in-patients-with-alk-positive-advanced-nsclc-cancer-nursing-today-ar/ 2026-07-20T11:10:45+00:00 https://keshavmed.com/news/identifying-biomarkers-of-therapeutic-resistance-with-lorlatinib-in-patients-with-alk-positive-advanced-nsclc-cancer-nursing-today-es/ 2026-07-20T11:10:42+00:00 https://keshavmed.com/news/identifying-biomarkers-of-therapeutic-resistance-with-lorlatinib-in-patients-with-alk-positive-advanced-nsclc-cancer-nursing-today-pt/ 2026-07-20T11:10:38+00:00 https://keshavmed.com/news/identifying-biomarkers-of-therapeutic-resistance-with-lorlatinib-in-patients-with-alk-positive-advanced-nsclc-cancer-nursing-today-ja/ 2026-07-20T11:10:36+00:00 https://keshavmed.com/news/identifying-biomarkers-of-therapeutic-resistance-with-lorlatinib-in-patients-with-alk-positive-advanced-nsclc-cancer-nursing-today-de/ 2026-07-20T11:10:32+00:00 https://keshavmed.com/news/identifying-biomarkers-of-therapeutic-resistance-with-lorlatinib-in-patients-with-alk-positive-advanced-nsclc-cancer-nursing-today-fr/ 2026-07-20T11:10:29+00:00 https://keshavmed.com/news/identifying-biomarkers-of-therapeutic-resistance-with-lorlatinib-in-patients-with-alk-positive-advanced-nsclc-cancer-nursing-today-zh-tw/ 2026-07-20T11:10:21+00:00 https://keshavmed.com/news/identifying-biomarkers-of-therapeutic-resistance-with-lorlatinib-in-patients-with-alk-positive-advanced-nsclc-cancer-nursing-today/ 2026-07-20T11:10:11+00:00 https://keshavmed.com/news/%e6%b3%8a%e7%ba%b3%e6%9b%bf%e5%b0%bc%e6%b2%bb%e7%96%97%e6%85%a2%e7%b2%92%e6%95%88%e6%9e%9c%e5%a5%bd%e5%90%97%ef%bc%9f%e5%89%af%e4%bd%9c%e7%94%a8%e3%80%81%e7%94%a8%e6%b3%95%e4%b8%8e%e8%b4%ad%e8%8d%af/ 2026-07-20T10:51:32+00:00 https://keshavmed.com/news/%e5%8f%b8%e6%9b%bf%e6%88%8a%e9%86%87%e5%b1%9e%e4%ba%8e%e5%93%aa%e7%b1%bb%e8%8d%af%e7%89%a9%ef%bc%8c%e6%b2%bb%e7%96%97%e5%a9%b4%e5%84%bf%e7%97%89%e6%8c%9b%e7%97%87%e6%95%88%e6%9e%9c%e6%80%8e%e4%b9%88/ 2026-07-20T10:50:38+00:00 https://keshavmed.com/news/%e9%98%bf%e5%9f%b9%e5%88%a9%e5%8f%b8%e6%b2%bb%e7%96%97%e6%bf%80%e7%b4%a0%e5%8f%97%e4%bd%93%e9%98%b3%e6%80%a7%e6%99%9a%e6%9c%9f%e4%b9%b3%e8%85%ba%e7%99%8c%e6%95%88%e6%9e%9c%e5%a5%bd%e5%90%97%e3%80%81/ 2026-07-20T10:49:47+00:00 https://keshavmed.com/news/%e9%98%bf%e7%ba%b3%e8%8e%ab%e6%9e%97%e6%b2%bb%e7%96%97%e7%99%8c%e7%97%87%e6%81%b6%e6%b6%b2%e8%b4%a8%e6%95%88%e6%9e%9c%e6%80%8e%e6%a0%b7%ef%bc%8c%e7%be%8e%e5%9b%bd%e9%a3%9f%e8%8d%af%e7%9b%91%e5%b1%80/ 2026-07-20T10:48:49+00:00 https://keshavmed.com/news/%e9%98%bf%e5%b8%83%e6%98%94%e6%9b%bf%e5%b0%bc%e6%b2%bb%e7%96%97%e4%b8%ad%e9%87%8d%e5%ba%a6%e7%89%b9%e5%ba%94%e6%80%a7%e7%9a%ae%e7%82%8e%e6%95%88%e6%9e%9c%e6%80%8e%e4%b9%88%e6%a0%b7%e5%89%af%e4%bd%9c/ 2026-07-20T10:45:52+00:00 https://keshavmed.com/news/%e7%b1%b3%e6%89%98%e5%9d%a6%e8%af%b4%e6%98%8e%e4%b9%a6%e8%af%a6%e8%a7%a3%ef%bc%9a%e6%b2%bb%e7%96%97%e8%82%be%e4%b8%8a%e8%85%ba%e7%9a%ae%e8%b4%a8%e7%99%8c%e7%9a%84%e7%96%97%e6%95%88%e3%80%81%e5%89%af/ 2026-07-20T10:44:43+00:00 https://keshavmed.com/news/%e5%88%a9%e6%9b%bf%e8%a5%bf%e6%9b%bf%e5%b0%bc%e6%b2%bb%e7%96%97%e6%96%91%e7%a7%83%e6%95%88%e6%9e%9c%e5%a5%bd%e5%90%97%ef%bc%9f%e5%89%af%e4%bd%9c%e7%94%a8%e3%80%81%e7%94%a8%e6%b3%95%e4%b8%8e%e4%bb%b7/ 2026-07-20T10:43:11+00:00 https://keshavmed.com/news/%e6%96%af%e5%b7%b4%e7%94%9f%e5%9d%a6%e6%b2%bb%e7%96%97%e5%85%8d%e7%96%ab%e7%90%83%e8%9b%8b%e7%99%bd%e6%b2%89%e7%a7%af%e6%80%a7%e8%82%be%e7%97%85%e6%95%88%e6%9e%9c%e5%a6%82%e4%bd%95%e5%89%af%e4%bd%9c/ 2026-07-20T10:42:17+00:00 https://keshavmed.com/news/%e8%89%be%e5%a5%88%e8%a5%bf%e5%b8%83%e6%b2%bb%e7%96%97%e6%80%a5%e6%80%a7%e9%ab%93%e7%b3%bb%e7%99%bd%e8%a1%80%e7%97%85%e6%95%88%e6%9e%9c%e6%80%8e%e4%b9%88%e6%a0%b7%e3%80%81%e9%80%82%e5%90%88%e5%93%aa/ 2026-07-20T10:39:44+00:00 https://keshavmed.com/news/%e5%a5%a5%e6%8b%89%e5%b8%95%e5%88%a9%e6%b2%bb%e7%96%97%e5%8d%b5%e5%b7%a2%e7%99%8c%e4%b8%8e%e4%b9%b3%e8%85%ba%e7%99%8c%e6%95%88%e6%9e%9c%e5%a6%82%e4%bd%95%ef%bc%8c%e5%89%af%e4%bd%9c%e7%94%a8%e5%8f%8a/ 2026-07-20T10:38:54+00:00 https://keshavmed.com/news/%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb%e7%96%97%e9%bb%91%e8%89%b2%e7%b4%a0%e7%98%a4%e6%95%88%e6%9e%9c%e6%80%8e%e4%b9%88%e6%a0%b7%e5%89%af%e4%bd%9c%e7%94%a8%e5%a4%a7%e5%90%97%e6%80%8e%e4%b9%88/ 2026-07-20T10:38:11+00:00 https://keshavmed.com/news/%e8%be%be%e6%8b%89%e9%9d%9e%e5%b0%bc%e8%81%94%e5%90%88%e6%9b%b2%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb%e7%96%97%e7%89%b9%e5%ae%9a%e5%9f%ba%e5%9b%a0%e7%aa%81%e5%8f%98%e9%bb%91%e8%89%b2%e7%b4%a0%e7%98%a4/ 2026-07-20T10:37:23+00:00 https://keshavmed.com/news/%e7%bb%b4%e5%a5%88%e5%85%8b%e6%8b%89%e6%b2%bb%e7%96%97%e6%85%a2%e6%80%a7%e6%b7%8b%e5%b7%b4%e7%bb%86%e8%83%9e%e7%99%bd%e8%a1%80%e7%97%85%e6%95%88%e6%9e%9c%e6%80%8e%e4%b9%88%e6%a0%b7%e3%80%81%e5%89%af/ 2026-07-20T10:36:29+00:00 https://keshavmed.com/news/%e5%a1%9e%e5%88%a9%e5%b0%bc%e7%b4%a2%e6%b2%bb%e7%96%97%e5%a4%9a%e5%8f%91%e6%80%a7%e9%aa%a8%e9%ab%93%e7%98%a4%e6%95%88%e6%9e%9c%e6%80%8e%e4%b9%88%e6%a0%b7%ef%bc%8c%e5%89%af%e4%bd%9c%e7%94%a8%e4%b8%8e/ 2026-07-20T10:35:15+00:00 https://keshavmed.com/news/%e5%a1%9e%e6%99%ae%e6%9b%bf%e5%b0%bc%e6%b2%bb%e7%96%97%e5%9f%ba%e5%9b%a0%e8%9e%8d%e5%90%88%e9%98%b3%e6%80%a7%e8%82%ba%e7%99%8c%e4%b8%8e%e7%94%b2%e7%8a%b6%e8%85%ba%e7%99%8c%ef%bc%9a%e7%96%97%e6%95%88/ 2026-07-20T10:34:16+00:00 https://keshavmed.com/news/%e6%9e%b8%e6%a9%bc%e9%85%b8%e4%bc%8a%e6%b2%99%e4%bd%90%e7%b1%b3%e6%b2%bb%e7%96%97%e5%a4%9a%e5%8f%91%e6%80%a7%e9%aa%a8%e9%ab%93%e7%98%a4%e6%95%88%e6%9e%9c%e6%80%8e%e4%b9%88%e6%a0%b7%e5%89%af%e4%bd%9c/ 2026-07-20T10:33:20+00:00 https://keshavmed.com/news/%e6%99%ae%e6%8b%89%e6%9b%bf%e5%b0%bc%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e8%82%ba%e8%85%ba%e7%99%8c%e6%95%88%e6%9e%9c%e6%80%8e%e4%b9%88%e6%a0%b7%e5%89%af%e4%bd%9c%e7%94%a8%e5%a4%a7%e5%90%97%e9%80%82/ 2026-07-20T10:32:29+00:00 https://keshavmed.com/news/%e5%9f%b9%e7%b1%b3%e5%90%89%e6%9b%bf%e5%b0%bc%e6%b2%bb%e7%96%97%e8%83%86%e7%ae%a1%e7%99%8c%e6%95%88%e6%9e%9c%e5%a5%bd%e5%90%97%ef%bc%9f%e9%80%82%e5%ba%94%e7%97%87%e3%80%81%e5%89%af%e4%bd%9c%e7%94%a8/ 2026-07-20T10:29:16+00:00 https://keshavmed.com/news/%e9%9d%9e%e5%a5%88%e5%88%a9%e9%85%ae%e6%b2%bb%e7%96%97%e7%b3%96%e5%b0%bf%e7%97%85%e8%82%be%e7%97%85%e6%95%88%e6%9e%9c%e5%a6%82%e4%bd%95%e3%80%81%e6%80%8e%e4%b9%88%e5%90%83%e3%80%81%e9%80%82%e5%90%88/ 2026-07-20T10:27:45+00:00 https://keshavmed.com/news/%e8%8e%ab%e5%8d%9a%e8%b5%9b%e6%9b%bf%e5%b0%bc%e6%b2%bb%e7%96%97%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e7%96%97%e6%95%88%e5%a6%82%e4%bd%95%ef%bc%9f%e5%89%af%e4%bd%9c%e7%94%a8%e3%80%81/ 2026-07-20T10:26:49+00:00 https://keshavmed.com/news/%e6%b4%9b%e6%8b%89%e6%9b%bf%e5%b0%bc%e6%b2%bb%e7%96%97%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%95%88%e6%9e%9c%e5%a5%bd%e5%90%97%ef%bc%9f%e5%89%af%e4%bd%9c%e7%94%a8%e3%80%81%e7%94%a8/ 2026-07-20T10:25:56+00:00 https://keshavmed.com/news/%e9%98%bf%e4%bc%90%e6%9b%b2%e6%b3%8a%e5%b8%95%e6%b2%bb%e7%96%97%e6%85%a2%e6%80%a7%e8%82%9d%e7%97%85%e8%a1%80%e5%b0%8f%e6%9d%bf%e5%87%8f%e5%b0%91%e6%95%88%e6%9e%9c%e6%80%8e%e4%b9%88%e6%a0%b7%e5%89%af/ 2026-07-20T10:24:57+00:00 https://keshavmed.com/news/%e5%85%8b%e5%94%91%e6%9b%bf%e5%b0%bc%e6%b2%bb%e7%96%97%e9%97%b4%e5%8f%98%e6%80%a7%e6%b7%8b%e5%b7%b4%e7%98%a4%e6%bf%80%e9%85%b6%e9%98%b3%e6%80%a7%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c/ 2026-07-20T10:23:49+00:00 https://keshavmed.com/news/%e7%b4%a2%e6%89%98%e6%8b%89%e8%a5%bf%e5%b8%83%e6%b2%bb%e7%96%97%e6%90%ba%e5%b8%a6%e7%89%b9%e5%ae%9a%e5%9f%ba%e5%9b%a0%e7%aa%81%e5%8f%98%e8%82%ba%e7%99%8c%e6%95%88%e6%9e%9c%e5%a5%bd%e5%90%97/ 2026-07-20T10:22:46+00:00 https://keshavmed.com/news/%e5%a5%a5%e5%b8%8c%e6%9b%bf%e5%b0%bc-80-%e6%af%ab%e5%85%8b%e6%b2%bb%e7%96%97%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e7%9a%84%e6%95%88%e6%9e%9c%e3%80%81%e5%89%af%e4%bd%9c%e7%94%a8/ 2026-07-20T10:20:54+00:00 https://keshavmed.com/news/%e8%89%be%e6%9b%b2%e6%b3%8a%e5%b8%95%e6%b2%bb%e7%96%97%e5%85%8d%e7%96%ab%e6%80%a7%e8%a1%80%e5%b0%8f%e6%9d%bf%e5%87%8f%e5%b0%91%e7%97%87%e6%95%88%e6%9e%9c%e5%a6%82%e4%bd%95%e3%80%81%e6%80%8e%e4%b9%88/ 2026-07-20T10:20:09+00:00 https://keshavmed.com/news/%e6%8b%89%e7%bd%97%e6%9b%bf%e5%b0%bc%e6%b2%bb%e7%96%97%e6%90%ba%e5%b8%a6%e7%89%b9%e5%ae%9a%e8%9e%8d%e5%90%88%e5%9f%ba%e5%9b%a0%e7%9a%84%e5%ae%9e%e4%bd%93%e7%98%a4%e6%95%88%e6%9e%9c%e6%80%8e%e4%b9%88/ 2026-07-20T10:19:34+00:00 https://keshavmed.com/news/%e7%b1%b3%e8%be%be%e7%be%8e%e6%9b%bf%e5%b0%bc%e6%b2%bb%e7%96%97%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e7%9a%84%e6%95%88%e6%9e%9c%e3%80%81%e5%89%af%e4%bd%9c%e7%94%a8%e4%b8%8e%e7%94%a8/ 2026-07-20T10:18:53+00:00 https://keshavmed.com/news/%e5%a4%9a%e8%be%be%e7%bb%b4%e6%99%ae%e9%85%ae%e7%94%a8%e8%8d%af%e5%85%a8%e8%a7%a3%e6%9e%90%ef%bc%9a%e9%80%82%e5%ba%94%e7%97%87%e3%80%81%e7%94%a8%e6%b3%95%e7%94%a8%e9%87%8f%e3%80%81%e5%89%af%e4%bd%9c/ 2026-07-20T10:18:20+00:00 https://keshavmed.com/news/%e9%98%bf%e6%9b%b2%e7%94%9f%e5%9d%a6%e6%b2%bb%e7%96%97%e5%85%8d%e7%96%ab%e7%90%83%e8%9b%8b%e7%99%bd%e6%b2%89%e7%a7%af%e6%80%a7%e8%82%be%e7%97%85%e6%95%88%e6%9e%9c%e5%a5%bd%e5%90%97%e5%89%af%e4%bd%9c/ 2026-07-20T10:17:01+00:00 https://keshavmed.com/news/fda-approves-lumakras-sotorasib-in-combination-with-vectibix-panitumumab-for-chemorefractory-kras-g12c-mutated-metastatic-colorectal-cancer-pr-newswire-vi/ 2026-07-20T09:37:17+00:00 https://keshavmed.com/news/fda-approves-lumakras-sotorasib-in-combination-with-vectibix-panitumumab-for-chemorefractory-kras-g12c-mutated-metastatic-colorectal-cancer-pr-newswire-ms/ 2026-07-20T09:37:17+00:00 https://keshavmed.com/news/fda-approves-lumakras-sotorasib-in-combination-with-vectibix-panitumumab-for-chemorefractory-kras-g12c-mutated-metastatic-colorectal-cancer-pr-newswire-id/ 2026-07-20T09:37:16+00:00 https://keshavmed.com/news/fda-approves-lumakras-sotorasib-in-combination-with-vectibix-panitumumab-for-chemorefractory-kras-g12c-mutated-metastatic-colorectal-cancer-pr-newswire-th/ 2026-07-20T09:37:16+00:00 https://keshavmed.com/news/fda-approves-lumakras-sotorasib-in-combination-with-vectibix-panitumumab-for-chemorefractory-kras-g12c-mutated-metastatic-colorectal-cancer-pr-newswire-ar/ 2026-07-20T09:37:15+00:00 https://keshavmed.com/news/fda-approves-lumakras-sotorasib-in-combination-with-vectibix-panitumumab-for-chemorefractory-kras-g12c-mutated-metastatic-colorectal-cancer-pr-newswire-ru/ 2026-07-20T09:37:15+00:00 https://keshavmed.com/news/fda-approves-lumakras-sotorasib-in-combination-with-vectibix-panitumumab-for-chemorefractory-kras-g12c-mutated-metastatic-colorectal-cancer-pr-newswire-es/ 2026-07-20T09:37:14+00:00 https://keshavmed.com/news/fda-approves-lumakras-sotorasib-in-combination-with-vectibix-panitumumab-for-chemorefractory-kras-g12c-mutated-metastatic-colorectal-cancer-pr-newswire-pt/ 2026-07-20T09:37:12+00:00 https://keshavmed.com/news/fda-approves-lumakras-sotorasib-in-combination-with-vectibix-panitumumab-for-chemorefractory-kras-g12c-mutated-metastatic-colorectal-cancer-pr-newswire-ja/ 2026-07-20T09:37:10+00:00 https://keshavmed.com/news/fda-approves-lumakras-sotorasib-in-combination-with-vectibix-panitumumab-for-chemorefractory-kras-g12c-mutated-metastatic-colorectal-cancer-pr-newswire-de/ 2026-07-20T09:37:08+00:00 https://keshavmed.com/news/fda-approves-lumakras-sotorasib-in-combination-with-vectibix-panitumumab-for-chemorefractory-kras-g12c-mutated-metastatic-colorectal-cancer-pr-newswire-fr/ 2026-07-20T09:37:06+00:00 https://keshavmed.com/news/fda-approves-lumakras-sotorasib-in-combination-with-vectibix-panitumumab-for-chemorefractory-kras-g12c-mutated-metastatic-colorectal-cancer-pr-newswire-zh-tw/ 2026-07-20T09:37:04+00:00 https://keshavmed.com/news/fda-approves-lumakras-sotorasib-in-combination-with-vectibix-panitumumab-for-chemorefractory-kras-g12c-mutated-metastatic-colorectal-cancer-pr-newswire/ 2026-07-20T09:37:01+00:00 https://keshavmed.com/news/sotorasib-at-960-mg-plus-panitumumab-emerges-as-soc-in-kras-g12c-mcrc-cancernetwork-ms/ 2026-07-20T09:35:38+00:00 https://keshavmed.com/news/sotorasib-at-960-mg-plus-panitumumab-emerges-as-soc-in-kras-g12c-mcrc-cancernetwork-vi/ 2026-07-20T09:35:36+00:00 https://keshavmed.com/news/sotorasib-at-960-mg-plus-panitumumab-emerges-as-soc-in-kras-g12c-mcrc-cancernetwork-th/ 2026-07-20T09:35:34+00:00 https://keshavmed.com/news/sotorasib-at-960-mg-plus-panitumumab-emerges-as-soc-in-kras-g12c-mcrc-cancernetwork-id/ 2026-07-20T09:35:32+00:00 https://keshavmed.com/news/sotorasib-at-960-mg-plus-panitumumab-emerges-as-soc-in-kras-g12c-mcrc-cancernetwork-ru/ 2026-07-20T09:35:30+00:00 https://keshavmed.com/news/sotorasib-at-960-mg-plus-panitumumab-emerges-as-soc-in-kras-g12c-mcrc-cancernetwork-ar/ 2026-07-20T09:35:28+00:00 https://keshavmed.com/news/sotorasib-at-960-mg-plus-panitumumab-emerges-as-soc-in-kras-g12c-mcrc-cancernetwork-es/ 2026-07-20T09:35:26+00:00 https://keshavmed.com/news/sotorasib-at-960-mg-plus-panitumumab-emerges-as-soc-in-kras-g12c-mcrc-cancernetwork-pt/ 2026-07-20T09:35:24+00:00